PDS Biotechnology (STU:EU6) Debt-to-Equity : 0.65 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology Debt-to-Equity?

PDS Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €6.76 Mil. PDS Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €15.42 Mil. PDS Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €34.21 Mil. PDS Biotechnology's debt to equity for the quarter that ended in Mar. 2024 was 0.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PDS Biotechnology's Debt-to-Equity or its related term are showing as below:

STU:EU6' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.12 Med: 0.06 Max: 0.96
Current: 0.65

During the past 11 years, the highest Debt-to-Equity Ratio of PDS Biotechnology was 0.96. The lowest was -0.12. And the median was 0.06.

STU:EU6's Debt-to-Equity is ranked worse than
79.81% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:EU6: 0.65

PDS Biotechnology Debt-to-Equity Historical Data

The historical data trend for PDS Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Debt-to-Equity Chart

PDS Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

0.53

0.91

PDS Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.57	0.73	0.96	0.91	0.65

Competitive Comparison of PDS Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, PDS Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDS Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Debt-to-Equity falls into.

PDS Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PDS Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.872	+	18)	/	23.962
	=	0.91

PDS Biotechnology's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.761	+	15.419)	/	34.208
	=	0.65

PDS Biotechnology (STU:EU6) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PDS Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology (STU:EU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PDSB:USA EU6:Germany

Address

25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology (STU:EU6) Headlines

No Headlines